Clearside Biomedical Announces Multiple Presentations on its Suprachoroidal Space® Injection Platform at Upcoming Medical Meetings
Viral Kansara, Ph.D., Clearside Vice President, Discovery, will give an oral presentation at the 6th Annual Retinal Cell and Gene Therapy Innovation Summit
Title: | Suprachoroidally delivered non-viral DNA nanoparticles transfect chorioretinal cells in non-human primates and rabbits |
Date: | Friday, April 26, 2019 |
Time: | 5:30 pm – 5:45 pm |
Title: | Suprachoroidal Administration of Triamcinolone Acetonide (CLS-TA) For the Treatment of Macular Edema in Noninfectious Uveitis: Pooled Results of Three Clinical Trials |
Date: | Saturday, April 27, 2019 |
Event Time: | 5:00 pm – 7:30 pm |
Three poster presentations will be made at the
Title: | Suprachoroidal injection of AAV8 for ocular gene delivery in the nonhuman primate |
Date: | Tuesday, April 30, 2019 |
Time: | 8:45 am – 10:30 am |
Session: | Gene Therapy and Delivery |
Poster #: | A0091 |
Abstract #: | 2904 - A0091 |
Title: | Suprachoroidally delivered non-viral DNA nanoparticles transfect chorioretinal cells in non-human primates and rabbits |
Date: | Tuesday, April 30, 2019 |
Time: | 8:45 am – 10:30 am |
Session: | Gene Therapy and Delivery |
Poster #: | A0096 |
Abstract #: | 2909 - A0096 |
Title: | Treatment response analysis of visual acuity and central subfield retinal thickness following suprachoroidal CLS-TA |
Date: | Tuesday, April 30, 2019 |
Time: | 11:45 am – 1:30 pm |
Session: | Uveitis and scleritis - clinical therapeutics and checkpoint inhibitors |
Poster #: | A0552 |
Abstract #: | 3511 - A0552 |
About
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Clearside’s current beliefs and expectations. These forward-looking statements include expectations regarding the potential benefits of SCS Injection Platform. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Clearside’s reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in Clearside’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the U.S. Securities and Exchange Commission (“SEC”) on March 15, 2019, and Clearside’s other Periodic Reports filed with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Clearside as of the date of this release, and Clearside assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor and Media Contacts:
ir@clearsidebio.com
(678) 430-8206
Source:
Source: Clearside Biomedical, Inc.